Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900305 | 0.79 | LRRK2 (0.36) | LRRK2PTGS1PIM1PIM2 | |
| SCHEMBL19900144 | 0.76 | ALDH1A1 (0.36) | FFAR4 | |
| SCHEMBL19900199 | 0.76 | CHRM3 (0.36) | FFAR4 | |
| SCHEMBL29732718 | 0.76 | CHRM3 (0.36) | FFAR4 | |
| SCHEMBL19127434 | 0.74 | LRRK2 (0.34) | LRRK2FFAR4HSD11B1 | |
| SCHEMBL19900152 | 0.72 | NAAA (0.33) | — | |
| SCHEMBL11788368 | 0.70 | PTGS1 (0.34) | LRRK2PTGS1 | |
| SCHEMBL8388467 | 0.67 | LRRK2 (0.36) | LRRK2PTGS1THRATHRB | |
| SCHEMBL29109990 | 0.66 | BRD4 (0.36) | LRRK2FFAR4 | |
| SCHEMBL16682879 | 0.64 | KDM4E (0.43) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595250-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-04-07 | — | — | US | disclosed |
| US-20220324841-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-09 | — | — | US | disclosed |
| WO-2018039077-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018039077-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595250-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | GSR, UQCRC1, TXNRD2 | LRRK2 1228/4885PTGS1 309/4885PIM1 4169/4885 |
| US-20220324841-A1 | THERAPEUTIC COMPOUNDS | CFTR, F12, FURIN | LRRK2 918/4885PTGS1 1301/4885PIM1 2030/4885 |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | CFTR, F12, FURIN | LRRK2 918/4885PTGS1 1301/4885PIM1 2030/4885 |
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | DPYD, TYMP, NUDT1 | LRRK2 2341/4885PTGS1 442/4885PIM1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.